Praxis Precision Medicines stock soars after early study halt for efficacy

view original post

In a separate announcement, Praxis revealed it successfully completed a pre-NDA meeting with the FDA regarding ulixacaltamide, its treatment for essential tremor. The company has gained alignment from …